Literature DB >> 27000845

Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer.

Ji Won Kim1, Yangsoon Park2, Jong-Lyel Roh3, Kyung-Ja Cho2, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1.   

Abstract

BACKGROUND: Glucosylceramide synthase (GCS) and P-glycoprotein (P-gp) overexpression are associated with multidrug resistance in several human cancers. This study investigated the prognostic value of GCS and P-gp in oral cavity squamous cell carcinoma (OSCC).
METHODS: The association between GCS and P-gp overexpression and clinical outcomes was assessed in 186 human clinical specimens of primary tumors obtained from curative surgery. Immunohistochemistry staining results were scored as high or low for GCS, and positive or negative for P-gp. Univariate and multivariate analyses using the Cox proportional hazards model were conducted to assess the significance of differences in recurrence or survival outcomes between variables.
RESULTS: GCS overexpression was observed in 128 (68.8 %) patients and P-gp overexpression in 43 (23.1 %) patients. High GCS expression was significantly correlated with P-gp immunopositivity (P = 0.005). GCS and P-gp overexpression was significantly correlated with cervical nodal metastasis (P < 0.05). Univariate analyses showed that tumor lymphovascular invasion, positive neck lymph nodes, advanced overall TNM stage, high GCS expression, and P-gp immunopositivity were associated with poor locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) (P < 0.05). Multivariate analyses showed that lymphovascular invasion, nodal positivity, and P-gp overexpression remained independent prognostic variables for LRC, DFS, and OS, and that GCS expression was an independent predictor of LRC and DFS (P < 0.05).
CONCLUSION: GCS and P-gp expression is associated with poor prognosis, suggesting suitability as novel biomarkers in OSCC.

Entities:  

Keywords:  Biomarker; Glucosylceramide synthase; Oral cavity cancer; P-glycoprotein; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27000845     DOI: 10.1007/s10147-016-0973-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  33 in total

Review 1.  Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.

Authors:  B I Sikic; G A Fisher; B L Lum; J Halsey; L Beketic-Oreskovic; G Chen
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

2.  Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.

Authors:  Valérie Gouazé; Yong-Yu Liu; Carlton S Prickett; Jing Y Yu; Armando E Giuliano; Myles C Cabot
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

Review 3.  Ceramide-orchestrated signalling in cancer cells.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

4.  MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells.

Authors:  Alba Rocco; Debora Compare; Eleonora Liguori; Alessandra Cianflone; Giuseppe Pirozzi; Virginia Tirino; Alessandra Bertoni; Margherita Santoriello; Corrado Garbi; Maria D'Armiento; Stefania Staibano; Gerardo Nardone
Journal:  Lab Invest       Date:  2012-07-02       Impact factor: 5.662

Review 5.  Metastasis of squamous cell carcinoma of the oral tongue.

Authors:  Daisuke Sano; Jeffrey N Myers
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

6.  P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis.

Authors:  R Ralhan; R K Swain; S Agarwal; J Kaur; N Nath; G Sarkar; M Mathur; N K Shukla
Journal:  Int J Cancer       Date:  1999-02-19       Impact factor: 7.396

7.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

8.  Coexpression of Ets-1 and p53 in oral carcinomas is associated with P-glycoprotein expression and poor prognosis.

Authors:  S Soni; P Pande; N K Shukla; R Ralhan
Journal:  J Cancer Res Clin Oncol       Date:  2002-04-24       Impact factor: 4.553

9.  Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma.

Authors:  Rolf Warta; Dirk Theile; Carolin Mogler; Esther Herpel; Niels Grabe; Bernd Lahrmann; Peter K Plinkert; Christel Herold-Mende; Johanna Weiss; Gerhard Dyckhoff
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

10.  A Higher Angiogenin Expression is Associated With a Nonnuclear Maspin Location in Laryngeal Carcinoma.

Authors:  Andrea Lovato; Marco Lionello; Alberto Staffieri; Stella Blandamura; Giulia Tealdo; Luciano Giacomelli; Claudia Staffieri; Gino Marioni
Journal:  Clin Exp Otorhinolaryngol       Date:  2015-08-13       Impact factor: 3.372

View more
  14 in total

1.  Circ_0000745 strengthens the expression of CCND1 by functioning as miR-488 sponge and interacting with HuR binding protein to facilitate the development of oral squamous cell carcinoma.

Authors:  Kuangzheng Li; Xiaosheng Fan; Ziyi Yan; Jia Zhan; Fangyun Cao; Yixia Jiang
Journal:  Cancer Cell Int       Date:  2021-05-21       Impact factor: 5.722

Review 2.  Sphingolipid metabolism in cancer signalling and therapy.

Authors:  Besim Ogretmen
Journal:  Nat Rev Cancer       Date:  2017-11-17       Impact factor: 60.716

Review 3.  Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?

Authors:  Wing-Kee Lee; Richard N Kolesnick
Journal:  Cell Signal       Date:  2017-07-04       Impact factor: 4.315

4.  lncRNA TUG1 promotes the development of oral squamous cell carcinoma by regulating the MAPK signaling pathway by sponging miR-593-3p.

Authors:  Lei Jiang; Bing Zhou; Dongjie Fu; Bo Cheng
Journal:  Cell Cycle       Date:  2022-05-23       Impact factor: 5.173

Review 5.  Sphingolipids and Lymphomas: A Double-Edged Sword.

Authors:  Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

6.  Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes.

Authors:  Nur Şebnem Ersöz; Aysun Adan
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

7.  Diagnostic Value of Semiquantitative Analysis of 99mTechnetium-Methoxyisobutylisonitrile (99mTc-MIBI) Imaging in Predicting Early-Stage Cervical Lymph Node Metastasis of Thyroid Carcinoma.

Authors:  Xiao-Chun Zhu; Kai Zhou; Shi-Qing Xu; Yu-Bo Ma
Journal:  Med Sci Monit       Date:  2017-03-31

Review 8.  Hallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma.

Authors:  Tomonori Sasahira; Tadaaki Kirita
Journal:  Int J Mol Sci       Date:  2018-08-16       Impact factor: 5.923

9.  Reduced ribosomal RNA expression and unchanged ribosomal DNA promoter methylation in oral squamous cell carcinoma.

Authors:  Shanshan Ha; Hong Zhou; Mayank Gautam; Yaling Song; Changning Wang
Journal:  Mol Genet Genomic Med       Date:  2019-06-06       Impact factor: 2.183

10.  MiR-210-3p-EphrinA3-PI3K/AKT axis regulates the progression of oral cancer.

Authors:  Lin Wang; Yong Song; Hui Wang; Ke Liu; Zhe Shao; Zhengjun Shang
Journal:  J Cell Mol Med       Date:  2020-03-17       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.